Submitted by Anonymous (not verified) on 21 August 2026 - 14:00
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised